241 related articles for article (PubMed ID: 17695724)
1. The ARF tumor suppressor in acute leukemias: insights from mouse models of Bcr-Abl-induced acute lymphoblastic leukemia.
Williams RT; Sherr CJ
Adv Exp Med Biol; 2007; 604():107-14. PubMed ID: 17695724
[TBL] [Abstract][Full Text] [Related]
2. Arf gene loss enhances oncogenicity and limits imatinib response in mouse models of Bcr-Abl-induced acute lymphoblastic leukemia.
Williams RT; Roussel MF; Sherr CJ
Proc Natl Acad Sci U S A; 2006 Apr; 103(17):6688-93. PubMed ID: 16618932
[TBL] [Abstract][Full Text] [Related]
3. Synergism between bosutinib (SKI-606) and the Chk1 inhibitor (PF-00477736) in highly imatinib-resistant BCR/ABL⁺ leukemia cells.
Nguyen T; Hawkins E; Kolluri A; Kmieciak M; Park H; Lin H; Grant S
Leuk Res; 2015 Jan; 39(1):65-71. PubMed ID: 25465126
[TBL] [Abstract][Full Text] [Related]
4. The INK4-ARF (CDKN2A/B) locus in hematopoiesis and BCR-ABL-induced leukemias.
Williams RT; Sherr CJ
Cold Spring Harb Symp Quant Biol; 2008; 73():461-7. PubMed ID: 19028987
[TBL] [Abstract][Full Text] [Related]
5. Targeting multiple kinase pathways in leukemic progenitors and stem cells is essential for improved treatment of Ph+ leukemia in mice.
Hu Y; Swerdlow S; Duffy TM; Weinmann R; Lee FY; Li S
Proc Natl Acad Sci U S A; 2006 Nov; 103(45):16870-5. PubMed ID: 17077147
[TBL] [Abstract][Full Text] [Related]
6. FTY720, a new alternative for treating blast crisis chronic myelogenous leukemia and Philadelphia chromosome-positive acute lymphocytic leukemia.
Neviani P; Santhanam R; Oaks JJ; Eiring AM; Notari M; Blaser BW; Liu S; Trotta R; Muthusamy N; Gambacorti-Passerini C; Druker BJ; Cortes J; Marcucci G; Chen CS; Verrills NM; Roy DC; Caligiuri MA; Bloomfield CD; Byrd JC; Perrotti D
J Clin Invest; 2007 Sep; 117(9):2408-21. PubMed ID: 17717597
[TBL] [Abstract][Full Text] [Related]
7. A farnesyltransferase inhibitor increases survival of mice with very advanced stage acute lymphoblastic leukemia/lymphoma caused by P190 Bcr/Abl.
Mishra S; Zhang B; Groffen J; Heisterkamp N
Leukemia; 2004 Jan; 18(1):23-8. PubMed ID: 14603339
[TBL] [Abstract][Full Text] [Related]
8. High-risk acute lymphoblastic leukemia cells with bcr-abl and INK4A/ARF mutations retain susceptibility to alloreactive T cells.
Young FM; Campbell A; Emo KL; Jansson J; Wang PY; Jordan CT; Mullen CA
Biol Blood Marrow Transplant; 2008 Jun; 14(6):622-30. PubMed ID: 18489987
[TBL] [Abstract][Full Text] [Related]
9. Phospho-CRKL monitoring for the assessment of BCR-ABL activity in imatinib-resistant chronic myeloid leukemia or Ph+ acute lymphoblastic leukemia patients treated with nilotinib.
La Rosée P; Holm-Eriksen S; Konig H; Härtel N; Ernst T; Debatin J; Mueller MC; Erben P; Binckebanck A; Wunderle L; Shou Y; Dugan M; Hehlmann R; Ottmann OG; Hochhaus A
Haematologica; 2008 May; 93(5):765-9. PubMed ID: 18367481
[TBL] [Abstract][Full Text] [Related]
10. ApoptomiRs expression modulated by BCR-ABL is linked to CML progression and imatinib resistance.
Ferreira AF; Moura LG; Tojal I; Ambrósio L; Pinto-Simões B; Hamerschlak N; Calin GA; Ivan C; Covas DT; Kashima S; Castro FA
Blood Cells Mol Dis; 2014; 53(1-2):47-55. PubMed ID: 24629639
[TBL] [Abstract][Full Text] [Related]
11. Resistance to imatinib of bcr/abl p190 lymphoblastic leukemia cells.
Mishra S; Zhang B; Cunnick JM; Heisterkamp N; Groffen J
Cancer Res; 2006 May; 66(10):5387-93. PubMed ID: 16707466
[TBL] [Abstract][Full Text] [Related]
12. Cytokine-dependent imatinib resistance in mouse BCR-ABL+, Arf-null lymphoblastic leukemia.
Williams RT; den Besten W; Sherr CJ
Genes Dev; 2007 Sep; 21(18):2283-7. PubMed ID: 17761812
[TBL] [Abstract][Full Text] [Related]
13. Requirement of Src kinases Lyn, Hck and Fgr for BCR-ABL1-induced B-lymphoblastic leukemia but not chronic myeloid leukemia.
Hu Y; Liu Y; Pelletier S; Buchdunger E; Warmuth M; Fabbro D; Hallek M; Van Etten RA; Li S
Nat Genet; 2004 May; 36(5):453-61. PubMed ID: 15098032
[TBL] [Abstract][Full Text] [Related]
14. Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl.
Weisberg E; Manley PW; Breitenstein W; Brüggen J; Cowan-Jacob SW; Ray A; Huntly B; Fabbro D; Fendrich G; Hall-Meyers E; Kung AL; Mestan J; Daley GQ; Callahan L; Catley L; Cavazza C; Azam M; Neuberg D; Wright RD; Gilliland DG; Griffin JD
Cancer Cell; 2005 Feb; 7(2):129-41. PubMed ID: 15710326
[TBL] [Abstract][Full Text] [Related]
15. Synergistic interactions between DMAG and mitogen-activated protein kinase kinase 1/2 inhibitors in Bcr/abl+ leukemia cells sensitive and resistant to imatinib mesylate.
Nguyen TK; Rahmani M; Gao N; Kramer L; Corbin AS; Druker BJ; Dent P; Grant S
Clin Cancer Res; 2006 Apr; 12(7 Pt 1):2239-47. PubMed ID: 16609040
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of dual-specific Bcr-Abl and Src-family kinase inhibitors in cells sensitive and resistant to imatinib mesylate.
Tipping AJ; Baluch S; Barnes DJ; Veach DR; Clarkson BM; Bornmann WG; Mahon FX; Goldman JM; Melo JV
Leukemia; 2004 Aug; 18(8):1352-6. PubMed ID: 15201856
[TBL] [Abstract][Full Text] [Related]
17. Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias.
Talpaz M; Shah NP; Kantarjian H; Donato N; Nicoll J; Paquette R; Cortes J; O'Brien S; Nicaise C; Bleickardt E; Blackwood-Chirchir MA; Iyer V; Chen TT; Huang F; Decillis AP; Sawyers CL
N Engl J Med; 2006 Jun; 354(24):2531-41. PubMed ID: 16775234
[TBL] [Abstract][Full Text] [Related]
18. Leukemia-associated translocation products able to activate RAS modify PML and render cells sensitive to arsenic-induced apoptosis.
Puccetti E; Beissert T; Güller S; Li JE; Hoelzer D; Ottmann OG; Ruthardt M
Oncogene; 2003 Oct; 22(44):6900-8. PubMed ID: 14534537
[TBL] [Abstract][Full Text] [Related]
19. Cotreatment with vorinostat (suberoylanilide hydroxamic acid) enhances activity of dasatinib (BMS-354825) against imatinib mesylate-sensitive or imatinib mesylate-resistant chronic myelogenous leukemia cells.
Fiskus W; Pranpat M; Balasis M; Bali P; Estrella V; Kumaraswamy S; Rao R; Rocha K; Herger B; Lee F; Richon V; Bhalla K
Clin Cancer Res; 2006 Oct; 12(19):5869-78. PubMed ID: 17020995
[TBL] [Abstract][Full Text] [Related]
20. Restoration of INK4a/ARF gene inhibits cell growth and cooperates with imatinib mesylate in Philadelphia chromosome-positive leukemias.
Bai Y; Lu Z; Lin Y; Sun B; Wang S; Wang G
Oncol Res; 2013; 21(1):23-31. PubMed ID: 24330849
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
